Technical Trend Overview and Price Movement
The stock closed at ₹8,217.20 on 4 May 2026, down 1.95% from the previous close of ₹8,381.00. Intraday volatility was evident with a high of ₹8,407.70 and a low of ₹8,107.35. Astrazeneca Pharma’s 52-week range remains broad, with a high of ₹10,653.05 and a low of ₹7,630.00, reflecting significant price fluctuations over the past year.
The technical trend has shifted from bearish to mildly bearish, indicating a slight easing of downward momentum but no clear reversal to bullishness. This nuanced change is reflected in the weekly and monthly technical indicators, which present a mixed picture for traders and investors.
MACD and RSI Signals
The Moving Average Convergence Divergence (MACD) remains bearish on the weekly timeframe, signalling that the short-term momentum is still under pressure. On the monthly scale, the MACD is mildly bearish, suggesting that while the longer-term trend is not strongly negative, it lacks robust upward momentum. This divergence between weekly and monthly MACD readings highlights the stock’s current indecision phase.
Relative Strength Index (RSI) readings on both weekly and monthly charts show no clear signals, hovering in neutral zones without indicating overbought or oversold conditions. This absence of RSI extremes suggests that the stock is neither strongly favoured for a rebound nor at immediate risk of a sharp decline based on momentum oscillators.
Bollinger Bands and Moving Averages
Bollinger Bands provide contrasting signals: weekly bands are bearish, indicating price pressure near the lower band and potential continuation of downward movement in the short term. Conversely, monthly Bollinger Bands are bullish, implying that on a longer horizon, the stock price is stabilising or potentially poised for a recovery.
Daily moving averages remain bearish, reinforcing the short-term negative momentum. The stock trading below key moving averages suggests resistance levels are intact, and any upward price moves may face selling pressure near these averages.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Additional Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator presents a split view: weekly readings are mildly bullish, hinting at some positive momentum building in the short term, while monthly readings remain mildly bearish, reflecting caution over the longer term. This divergence underscores the stock’s current technical uncertainty.
Dow Theory assessments align with this mixed outlook, showing mildly bullish signals on the weekly chart but mildly bearish on the monthly timeframe. This suggests that while short-term price action may be improving, the broader trend remains under pressure.
On-Balance Volume (OBV) indicators are mildly bearish on both weekly and monthly scales, indicating that volume trends are not supporting a strong price rally. The lack of volume confirmation for price gains is a warning sign for investors seeking sustainable upward momentum.
Comparative Performance Against Sensex
Examining Astrazeneca Pharma’s returns relative to the Sensex provides further context for its technical signals. Over the past week, the stock declined by 2.75%, underperforming the Sensex’s 0.97% drop. However, over the last month, Astrazeneca Pharma gained 5.90%, slightly lagging the Sensex’s 6.90% rise.
Year-to-date, the stock has fallen 8.80%, marginally outperforming the Sensex’s 9.75% decline. Over one year, Astrazeneca Pharma’s return of -5.11% trails the Sensex’s -4.15%, reflecting sector-specific challenges. Notably, the stock has delivered exceptional long-term gains, with a 3-year return of 157.60% compared to the Sensex’s 25.86%, a 5-year return of 110.40% versus 57.67%, and a remarkable 10-year return of 614.60% against the Sensex’s 200.37%.
This long-term outperformance highlights the company’s underlying growth potential despite recent technical headwinds.
Mojo Score and Grade Update
MarketsMOJO’s latest assessment assigns Astrazeneca Pharma a Mojo Score of 42.0, categorising it as a Sell. This represents a downgrade from the previous Hold rating effective 2 January 2026. The downgrade reflects the deteriorating technical parameters and cautious outlook from a risk-reward perspective, particularly given the small-cap status of the company within the Pharmaceuticals & Biotechnology sector.
Investors should weigh this technical downgrade alongside the company’s fundamental prospects and sector dynamics before making allocation decisions.
Holding Astrazeneca Pharma India Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaways and Outlook
In summary, Astrazeneca Pharma India Ltd’s technical indicators reveal a stock in transition, with short-term bearishness easing to a mildly bearish stance but longer-term signals remaining cautious. The divergence between weekly and monthly indicators such as MACD, Bollinger Bands, and KST suggests that investors should monitor price action closely for confirmation of trend direction.
The absence of strong RSI signals and the bearish daily moving averages imply that any rallies may be met with resistance, while volume trends as indicated by OBV do not currently support a sustained uptrend. The downgrade in Mojo Grade to Sell further emphasises the need for prudence.
However, Astrazeneca Pharma’s impressive long-term returns relative to the Sensex highlight its potential as a growth stock within the Pharmaceuticals & Biotechnology sector. Investors with a longer horizon may consider these fundamentals alongside technical signals to time entries and exits more effectively.
Given the mixed technical landscape, a cautious approach with close attention to weekly momentum shifts and volume confirmation is advisable. Monitoring key support levels near ₹7,630 and resistance around ₹8,400 will be critical in assessing the stock’s next directional move.
Conclusion
Astrazeneca Pharma India Ltd currently exhibits a complex technical profile characterised by a shift to mildly bearish momentum, mixed indicator signals, and a recent downgrade in rating. While short-term price action remains under pressure, longer-term fundamentals and historical outperformance provide a counterbalance. Investors should adopt a measured stance, integrating technical analysis with fundamental insights to navigate the evolving market conditions effectively.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
